MedTrace Logo

Hair Loss Prevention Study for Pancreatic Cancer

NCT04492800 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-05-26

Study results available
· View outcomes & findings →

Summary

Pilot study intended for hair loss prevention in patients with pancreatic cancer who are receiving treatment containing nab-paclitaxel, gemcitabine and cisplatin.

Conditions

Interventions

DEVICE

Paxman Scalp Cooling Device

Cooling will consist of precooling (30 minutes); infusion cooling (will vary depending upon the length of time to infuse the chemotherapy) and post infusion cooling (90 minutes).

Sponsors & Collaborators

  • HonorHealth Research Institute

    lead OTHER

Principal Investigators

  • Amy Mirabella, PhD, RN, CHPN · HonorHealth Research Institute - Bisgrove

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-13
Primary Completion
2021-04-20
Completion
2021-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04492800 on ClinicalTrials.gov